Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
856 questions in 87 reviews · Cystic Fibrosis and Genetic Disorders
current versionsNo studies 856 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Angiotensin‐converting enzyme inhibitors vs placebo All‐cause mortality · people with sickle cell disease Interventions for chronic kidney disease in people with sickle cell disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Angiotensin‐converting enzyme inhibitors vs placebo Quality of life · people with sickle cell disease Interventions for chronic kidney disease in people with sickle cell disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Full‐mouth ultrasonic scaling plus photodynamic therapy vs full‐mouth ultrasonic scaling alone Change in class of malocclusion · people with thalassaemia Treatment of dental and orthodontic complications in thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Full‐mouth ultrasonic scaling plus photodynamic therapy vs full‐mouth ultrasonic scaling alone Resolution or reduction in severity of any other dental complication: reduction in DMFT index · people with thalassaemia Treatment of dental and orthodontic complications in thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Full‐mouth ultrasonic scaling plus photodynamic therapy vs full‐mouth ultrasonic scaling alone Resolution or reduction in severity of any other dental complication: reduction in severity of periodontitis (measured by reduction in clinical attachment loss) · people with thalassaemia Treatment of dental and orthodontic complications in thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Full‐mouth ultrasonic scaling plus photodynamic therapy vs full‐mouth ultrasonic scaling alone Resolution or reduction in severity of any other dental complication: oral infections (measured by reduction in or resolution of lesions such as periapical cysts, abscesses, or space infections) · people with thalassaemia Treatment of dental and orthodontic complications in thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Full‐mouth ultrasonic scaling plus photodynamic therapy vs full‐mouth ultrasonic scaling alone Resolution or reduction in severity of any other dental complication: systemic infections (measured by number of episodes after treatment for dental complications under antibiotic prophylaxis) · people with thalassaemia Treatment of dental and orthodontic complications in thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Full‐mouth ultrasonic scaling plus photodynamic therapy vs full‐mouth ultrasonic scaling alone Any other adverse effects related to treatment · people with thalassaemia Treatment of dental and orthodontic complications in thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Alglucosidase alfa plus clenbuterol vs alglucosidase alfa plus placebo Infusion reactions · 13 people with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Alglucosidase alfa plus clenbuterol vs alglucosidase alfa plus placebo Need for respiratory support · 13 people with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Alglucosidase alfa plus clenbuterol vs alglucosidase alfa plus placebo Use of a walking aid / wheelchair · 13 people with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Alglucosidase alfa plus clenbuterol vs alglucosidase alfa plus placebo QoL · 13 people with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Alglucosidase alfa plus clenbuterol vs alglucosidase alfa plus placebo Treatment‐related adverse events · 13 people with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Alglucosidase alfa plus albuterol vs alglucosidase alfa plus placebo Infusion reactions · 13 people with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Alglucosidase alfa plus albuterol vs alglucosidase alfa plus placebo Need for respiratory support · 13 people with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Alglucosidase alfa plus albuterol vs alglucosidase alfa plus placebo Use of a walking aid / wheelchair · 13 people with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Alglucosidase alfa plus albuterol vs alglucosidase alfa plus placebo QoL · 13 people with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |
VAL‐1221 vs alglucosidase alfa Change in FVC (% predicted) · adults with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |
VAL‐1221 vs alglucosidase alfa Need for respiratory support · adults with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |
VAL‐1221 vs alglucosidase alfa Use of a walking aid/wheelchair · adults with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |
VAL‐1221 vs alglucosidase alfa QoL · adults with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |
VAL‐1221 vs alglucosidase alfa Treatment‐related adverse events · adults with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Cipaglucosidase plus miglustat vs alglucosidase alfa plus placebo Need for respiratory support · adults with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Cipaglucosidase plus miglustat vs alglucosidase alfa plus placebo Use of a walking aid / wheelchair · adults with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Alglucosidase alfa vs placebo Need for respiratory support · 90 people with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Avalglucosidase alfa vs alglucosidase alfa Need for respiratory support · adults with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Avalglucosidase alfa vs alglucosidase alfa Use of a walking aid / wheelchair · adults with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Alglucosidase alfa vs placebo Use of a walking aid/wheelchair · 90 people with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Motivational interventions to improve adherence to airway clearance treatment for people with CF ‐ self‐selected music vs no music Frequency of non‐hospitalised respiratory infection · people with CF Interventions for improving adherence to airway clearance treatment and exercise in people with cystic… (2023) · Cochrane | no estimate extracted | NR | No studies |
Motivational interventions to improve adherence to airway clearance treatment for people with CF ‐ self‐selected music vs no music FEV1 % predicted (change from baseline) · people with CF Interventions for improving adherence to airway clearance treatment and exercise in people with cystic… (2023) · Cochrane | no estimate extracted | NR | No studies |
Motivational interventions to improve adherence to airway clearance treatment for people with CF ‐ self‐selected music vs no music FVC % predicted (change from baseline) · people with CF Interventions for improving adherence to airway clearance treatment and exercise in people with cystic… (2023) · Cochrane | no estimate extracted | NR | No studies |
Motivational interventions to improve adherence to airway clearance treatment for people with CF ‐ self‐selected music vs no music QoL (change from baseline) · people with CF Interventions for improving adherence to airway clearance treatment and exercise in people with cystic… (2023) · Cochrane | no estimate extracted | NR | No studies |
Motivational interventions to improve adherence to airway clearance treatment for people with CF ‐ self‐selected music vs no music Exercise capacity (change from baseline) · people with CF Interventions for improving adherence to airway clearance treatment and exercise in people with cystic… (2023) · Cochrane | no estimate extracted | NR | No studies |
Motivational interventions to improve adherence to airway clearance treatment for people with CF ‐ specifically‐composed music vs self‐selected music Frequency of non‐hospitalised respiratory infection · people with CF Interventions for improving adherence to airway clearance treatment and exercise in people with cystic… (2023) · Cochrane | no estimate extracted | NR | No studies |
Motivational interventions to improve adherence to airway clearance treatment for people with CF ‐ specifically‐composed music vs self‐selected music FEV1 % predicted (change from baseline) · people with CF Interventions for improving adherence to airway clearance treatment and exercise in people with cystic… (2023) · Cochrane | no estimate extracted | NR | No studies |
Motivational interventions to improve adherence to airway clearance treatment for people with CF ‐ specifically‐composed music vs self‐selected music FVC % predicted (change from baseline) · people with CF Interventions for improving adherence to airway clearance treatment and exercise in people with cystic… (2023) · Cochrane | no estimate extracted | NR | No studies |
Motivational interventions to improve adherence to airway clearance treatment for people with CF ‐ specifically‐composed music vs self‐selected music QoL (change from baseline) · people with CF Interventions for improving adherence to airway clearance treatment and exercise in people with cystic… (2023) · Cochrane | no estimate extracted | NR | No studies |
Motivational interventions to improve adherence to airway clearance treatment for people with CF ‐ specifically‐composed music vs self‐selected music Exercise capacity (change from baseline) · people with CF Interventions for improving adherence to airway clearance treatment and exercise in people with cystic… (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Frequency of hospitalisation for respiratory infection · people with CF Interventions for improving adherence to airway clearance treatment and exercise in people with cystic… (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Frequency of non‐hospitalised respiratory infection · people with CF Interventions for improving adherence to airway clearance treatment and exercise in people with cystic… (2023) · Cochrane | no estimate extracted | NR | No studies |
Motivational interventions to improve adherence to airway clearance treatment for people with CF ‐ specifically‐composed music vs no music Frequency of non‐hospitalised respiratory infection · people with CF Interventions for improving adherence to airway clearance treatment and exercise in people with cystic… (2023) · Cochrane | no estimate extracted | NR | No studies |
Motivational interventions to improve adherence to airway clearance treatment for people with CF ‐ specifically‐composed music vs no music FEV1 % predicted (change from baseline) · people with CF Interventions for improving adherence to airway clearance treatment and exercise in people with cystic… (2023) · Cochrane | no estimate extracted | NR | No studies |
Motivational interventions to improve adherence to airway clearance treatment for people with CF ‐ specifically‐composed music vs no music FVC % predicted (change from baseline) · people with CF Interventions for improving adherence to airway clearance treatment and exercise in people with cystic… (2023) · Cochrane | no estimate extracted | NR | No studies |
Motivational interventions to improve adherence to airway clearance treatment for people with CF ‐ specifically‐composed music vs no music QoL (change from baseline) · people with CF Interventions for improving adherence to airway clearance treatment and exercise in people with cystic… (2023) · Cochrane | no estimate extracted | NR | No studies |
Motivational interventions to improve adherence to airway clearance treatment for people with CF ‐ specifically‐composed music vs no music Exercise capacity (change from baseline) · people with CF Interventions for improving adherence to airway clearance treatment and exercise in people with cystic… (2023) · Cochrane | no estimate extracted | NR | No studies |
Digital technology (TIM) vs standard treatment (TBM) Treatment burden · children aged 5 to 16 years Digital technology for monitoring adherence to inhaled therapies in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Digital technology (TIM) vs standard treatment (TBM) QoL · children aged 5 to 16 years Digital technology for monitoring adherence to inhaled therapies in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Digital technology (TIM) vs standard treatment (TBM) Number of pulmonary exacerbations · children aged 5 to 16 years Digital technology for monitoring adherence to inhaled therapies in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: psychological interventions vs an active comparator Treatment‐related adverse events Anxiety · adults (aged 16 years and over) with CF Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: psychological interventions vs an active comparator Treatment‐related adverse events Depression · adults (aged 16 years and over) with CF Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |